OPTIONS Act

1) WHAT HAPPENED: On April 15, 2026, Rep. Steube (R-FL) and cosponsor DelBene (D-WA) introduced the OPTIONS Act (HR8314), which was referred to the House Committee on Ways and Means. The bill is at the earliest legislative stage with only 1 cosponsor and zero committee markups or hearings. 2) MONEY TRAIL: The bill provides zero appropriated funding and zero authorized spending. It is a tax code amendment — not a spending bill. The mechanism is a regulatory change allowing employers to offer employees a choice among tax-favored benefit contributions (HSAs, HRAs, 401(k)/403(b) plans, educational assistance) without the employee being taxed on the options not taken. No federal dollars flow; the fiscal impact is a reduction in income tax revenue from increased HSA/HRA contributions. 3) STRUCTURAL WINNERS AND LOSERS: The bill is structurally positive for custodians and administrators of HSAs and HRAs (tickers not listed because publicly traded pure-play HSA/HRA administrators are limited; large banks like $JPM, $BAC, and $SCHW offer HSA services but this bill is too indirect to assign a causal chain). The bill is structurally negative for commercial health insurers , $CI, $ELV because accelerating the shift from defined-benefit group insurance to defined-contribution HSA/HRA accounts reduces employer-sponsored fully-insured premium pools. $UNH is excluded because its UnitedHealthcare segment is similarly exposed but the company's larger Optum revenue (health services, PBM) partially offsets; the causal chain is weaker. 4) REAL MARKET DATA CONTEXT: at $238.25 is up 37.41% in 30 days — this rally is unrelated to the OPTIONS Act (introduced April 15 when was $205.14; the bill had no detectable effect on price action). $CI at $291.77 is up 9.38% in 30 days; $ELV at $373.62 is up 27.62% in 30 days. These moves correlate with broader sector momentum and earnings season, not this early-stage procedural bill. 5) TIMELINE: The bill requires Ways and Means Committee markup, House floor vote, Senate introduction and passage through Finance Committee, Senate floor vote, then Presidential action. Likely timeline: zero probability of enactment in the current session given the 1-cosponsor start, late-session introduction, and no companion bill in the Senate.